---
document_datetime: 2023-09-21 18:01:32
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/exubera-epar-procedural-steps-taken-authorisation_en.pdf
document_name: exubera-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5844101
conversion_datetime: 2025-12-19 23:26:18.763899
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  applicant  Aventis/Pfizer  EEIG  submitted  on    5  February  2004  an  application  for  Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Exubera, in  accordance  with  the  centralised  procedure  falling  within  the  scope  of  Part  A  of  the  Annex  to Council Regulation No (EEC) 2309/93 of 22 July 1993.

•

- The applicant submitted the responses to the CHMP list of remaining outstanding issues to be addressed in writing on 14 September 2005.

Medicinal product no longer authorised The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: Rapporteur:  Dr. Gottfried Kreutz Co-Rapporteur: Dr. Pieter Neels Licensing status: The product was not licensed in any country at the time of submission of the application. 2. Steps taken for the assessment of the product · The application was received by the EMEA on 5 February 2004. · The procedure started on 23 February 2004. · The Rapporteur's first Assessment Report was circulated to all CHMP members on 7 May 2004. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 16 May 2004. · During  the  meeting  on  22-23  June  2004,  the  CHMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on  25 June 2004. · The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 21 October 2004. · The summary report of the inspection carried out at the manufacturing site Nektar Therapeutics, San Carlos, USA and Pfizer Inc., Terre Haute, USA between 15-17 and 20-22 September 2004 was issued on 8 November 2004. · The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on  20 January 2005 and 24 January 2005. · During the CHMP meeting on 17 February 2005, the CHMP agreed on a list of outstanding issues to be addressed in writing by the applicant. · The applicant submitted the responses to the CHMP list of outstanding issues to be addressed in writing on 13 May 2005. · The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the list of outstanding issues on 3 June 2005. · During the QWP meeting on 07-09 June 2005, outstanding quality issues were addressed by the applicant during an oral clarification before the QWP. · During  the  Ad-hoc  Expert  Group  meeting  on  15  June  2005,  clinical  safety  concerns  were discussed with external experts. · During  the  CHMP  meeting  on  21-23  June  2005,  outstanding  issues  were  addressed  by  the applicant during an oral explanation before the CHMP. During  the  CHMP  meeting  on  21-23  June  2005,  the  CHMP  agreed  on  a  list  of  remaining outstanding issues to be addressed in writing by the applicant.

- During  the  Ad-hoc  Expert  Risk  Management  Plan  meeting  on  28  September  2005,  safety concerns addressed in the risk management plan were discussed with external experts.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the list of remaining outstanding issues dated 28 September 2005.
- During  the  meeting  on    11-13  October  2005,  the  CHMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for

<div style=\"page-break-after: always\"></div>

granting a Marketing Authorisation to Exubera on 13 October 2005. The applicant provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 13 October 2005.

- The CHMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 24 January 2006.

<!-- image -->